Literature DB >> 12781431

Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone.

Branislav Jeremic1, Yuta Shibamoto, Biljana Milicic, Aleksandar Dagovic, Nebojsa Nikolic, Jasna Aleksandrovic, Ljubisa Acimovic, Slobodan Milisavljevic.   

Abstract

We investigated the effect of treatment interruptions due to high-grade (> or =3) toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy (Hfx RT). Of 116 patients treated with total tumour doses of 69.6 Gy, 1.2 Gy b.i.d. fractionation, 44 patients refused surgery while 72 patients were medically inoperable due to existing co-morbid states. Patients who were medically inoperable had worse KPS (P=0.0059) and more pronounced weight loss (P=0.0005). Among them, 12 patients experienced high-grade toxicity and 11 of them with either acute (n=6) or "consequential" late (n=5) high-grade toxicity requested interruption in the Hfx RT course (range, 12-25 days; median, 17 days). Superior survival (OS) was observed in patients who refused surgery when compared to those who were medically inoperable (P=0.0041), as well as superior local recurrence-free survival (LRFS) (P=0.011), but not different distant metastasis-free survival (P=0.14). Cause-specific survival (CSS) also favoured patients who refused surgery (P=0.004). Multivariate analysis showed independent influence of the reason for not undergoing surgery on OS (P=0.035), but not on LRFS (P=0.084) or CSS (P=0.068). Patients who refused surgery did not experience high-grade toxicity (0/44), whereas 11 of 72 patients with medical inoperability and co-morbid states experienced high-grade toxicity and had treatment interruptions to manage toxicity (P=0.0064). Patients without treatment interruptions had significantly better OS (P=0.00000), LRFS (P=0.00000) and CSS (P=0.00000) than those with treatment interruptions. When corrected for treatment interruptions, the reason for not undergoing surgery independently influenced OS (P=0.040), but not LRFS (P=0.092) or CSS (P=0.068). In contrast to this, treatment interruption was independent prognosticator of all three endpoints used (P=0.00031, P=0.0075 and P=0.00033, respectively). When 11 patients with treatment interruptions were excluded, the reason for not undergoing surgery still affected OS (P=0.037) and CSS (P=0.039) but not LRFS (P=0.11). Multivariate analyses using OS, CSS and LRFS showed that the reason for not undergoing surgery affected OS (P=0.0436), but neither CSS (P=0.083) nor LRFS (P=0.080).

Entities:  

Mesh:

Year:  2003        PMID: 12781431     DOI: 10.1016/s0169-5002(03)00078-3

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Authors:  Matthew P Deek; Sinae Kim; Inaya Ahmed; Bruno S Fang; Wei Zou; Jyoti Malhotra; Joseph Aisner; Salma K Jabbour
Journal:  Am J Clin Oncol       Date:  2018-04       Impact factor: 2.339

Review 2.  [Delays and treatment interruptions: difficulties in administering radiotherapy in an ideal time-period].

Authors:  Carmen González San Segundo; Felipe A Calvo Manuel; Juan Antonio Santos Miranda
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

Review 3.  Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).

Authors:  Victor Y Yazbeck; Liza Villaruz; Marsha Haley; Mark A Socinski
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

Review 4.  Protecting pediatric oncology patients from influenza.

Authors:  Leslie S Kersun; Anne F Reilly; Susan E Coffin; Kathleen E Sullivan
Journal:  Oncologist       Date:  2013-01-31

5.  Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.

Authors:  Jeffrey A Bogart; Dorothy Watson; Edward F McClay; Lisa Evans; James E Herndon; Frances Laurie; Stephen L Seagren; T J Fitzgerald; Everett Vokes; Mark R Green
Journal:  Lung Cancer       Date:  2008-03-25       Impact factor: 5.705

6.  Stereotactic Body Radiotherapy (SBRT) with Lower Doses for Selected Patients with Stage I Non-small-cell Lung Cancer (NSCLC).

Authors:  Stefan Janssen; Lukas Kaesmann; Volker Rudat; Dirk Rades
Journal:  Lung       Date:  2016-02-03       Impact factor: 2.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.